History & Overview Annual Report President's Pages Center News Community Affairs
Make a Gift Fred's Team Donating Blood & Platelets Volunteering Thrift Shop Park Avenue Potluck Cookbook
Press Releases Information for Journalists News@MSKCC
Manhattan New Jersey Long Island Westchester
Working at Memorial Sloan-Kettering Work Sites College Recruitment About Nursing Job Fairs & Career Days Job Search & Apply Online
Making an Appointment

Also Known As: Ifex®


Class: Alkylating agent


Late Effect (1st of 4)

  • Decreased functioning of the ovaries in females or testes in males (hypogonadism)
  • Infertility
  • Early menopause

Your risk is greater if:

  • You are male.
  • You are female and were treated during or after puberty.
  • It was combined with
    - Other alkylating agents
    - Radiation to the testicles, pelvis, or total body
  • You received a high dose of the drug.

Recommended Evaluation

  • History and physical exam, especially sexual history in males and menstrual history in females yearly
  • Hormone levels (females - FSH, LH, estradiol; males - LH, FSH, testosterone), and semen analysis as indicated based on need

Management

  • Because of the risk of early menopause, females should carefully weigh a decision to delay childbearing.
  • You may need a referral to a reproductive endocrinologist for fertility concerns. Sometimes, recovery of fertility may occur spontaneously many years after treatment.
  • Your doctor may recommend a bone mineral density to see if you have osteopenia or osteoporosis.
  • You may benefit from hormone replacement therapy; discuss it with your doctor.

Late Effect (2nd of 2)

Acute myeloid leukemia (AML)

Your risk is greater if:

  • It has been less than 10 years since you finished treatment. (It is more common in first 10 years.)
  • You received a high cumulative dose or if you also received other alkylating agents, especially melphalan or mechlorethamine.

Recommended Evaluation

  • Physical exam yearly
  • Complete blood count and differential yearly for up to 15 years
  • Evaluation of symptoms of fatigue, pallor, petechiae (small red rash), and bone pain
  • A bone marrow exam if you have any symptoms.

Management

  • If you are diagnosed with AML, you will be referred to a medical or pediatric oncologist for treatment.

Late Effect (3rd of 4)

Bladder problems (bleeding, dysfunctional voiding, malignancy)

Your risk is greater if:

  • You also received radiation to the pelvis.
  • You received a high dose.
  • You had bleeding from your bladder during treatment.
  • You drink alcoholic beverages.
  • You use tobacco.

Recommended Evaluation

  • Urinalysis yearly
  • Evaluation of painful urination or blood in the urine

Management

  • You may need a urology consultation.

Late Effect (4th of 4)

Kidney problems (possibly leading to kidney failure)

Your risk is greater if:

  • You received a dose greater than 60 gm/m².
  • You were younger than 5 years when you were treated.
  • You also received other drugs that can harm your kidneys (e.g., cisplatin, carboplatin, amphotericin B).
  • The tumor invaded the kidney.
  • If you have had kidney problems unrelated to your cancer diagnosis or treatment.

Recommended Evaluation

  • Blood pressure yearly
  • Blood tests of your kidney function at the end of treatment and repeated yearly
  • Immediate evaluation for symptoms of a urinary tract infection

Management

  • Drink plenty of fluids.
  • You may need to take electrolyte supplements.
  • Discuss any new medication, supplements, or herbals with a doctor who is knowledgeable about the side effects of ifosfamide before taking them.
  • You may need a referral to a kidney specialist (nephrologist).
Return to Chemotherapy Main Page
PrintEmail This Page